Cargando…

Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines

Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that a polyvalent Env formulation was able to elicit broadly reactive antibody responses including low titer neutralizing antibody responses against viral isolates of subtypes A, B, C and AE. In the current report,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shixia, Chou, Te-hui, Hackett, Anthony, Efros, Veronica, Wang, Yan, Han, Dong, Wallace, Aaron, Chen, Yuxin, Hu, Guangnan, Liu, Shuying, Clapham, Paul, Arthos, James, Montefiori, David, Lu, Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5718816/ https://www.ncbi.nlm.nih.gov/pubmed/28933684 http://dx.doi.org/10.1080/21645515.2017.1380137

Ejemplares similares

Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains
por: Wang, Shixia, et al.
Publicado: (2023)

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
por: Rouphael, Nadine G., et al.
Publicado: (2019)

Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters
por: Azizi, Ali, et al.
Publicado: (2006)

Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen
por: Sakhatskyy, Pavlo, et al.
Publicado: (2006)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost
por: Hutnick, NA, et al.
Publicado: (2012)

Rational modification of an HIV-1 gp120 results in enhanced neutralization breadth when used as a DNA prime
por: Wallace, A, et al.
Publicado: (2012)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding
por: Pan, Ruimin, et al.
Publicado: (2015)

Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates
por: Marcus, Hadar, et al.
Publicado: (2021)

Hyperglycosylated gp120 mutants elicit improved CD4-binding site directed antibodies in a heterologous prime:boost regimen
por: Ahmed, FK, et al.
Publicado: (2012)

Prime-Boost Immunization of Rabbits with HIV-1 gp120 Elicits Potent Neutralization Activity against a Primary Viral Isolate
por: Narayan, Kristin M., et al.
Publicado: (2013)

Signal peptide of HIV envelope protein impacts glycosylation and antigenicity of gp120
por: Yolitz, Jason, et al.
Publicado: (2018)

Comparative Immunogenicity of HIV-1 Clade C Envelope Proteins for Prime/Boost Studies
por: Smith, Douglas H., et al.
Publicado: (2010)

Immunogenicity of the outer domain of a HIV-1 clade C gp120
por: Chen, Hongying, et al.
Publicado: (2007)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses
por: Li, Haiying, et al.
Publicado: (2021)

Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions
por: Wang, Shixia, et al.
Publicado: (2020)

The dynamics of immunoglobulin V-gene usage and clonotype expansion in mice after prime and boost immunizations as analyzed by NGS
por: Farfán-Arribas, Diego J., et al.
Publicado: (2017)

Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α(4)β(7)
por: Lertjuthaporn, Sakaorat, et al.
Publicado: (2018)

Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques
por: Bowles, Emma J., et al.
Publicado: (2014)

Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials
por: Yu, Bin, et al.
Publicado: (2012)

Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector
Publicado: (2020)

The HIV-1 envelope protein gp120 is captured and displayed for B cell recognition by SIGN-R1(+) lymph node macrophages
por: Park, Chung, et al.
Publicado: (2015)

TRAIL Dependent Fratricidal Killing of gp120 Primed Hepatocytes by HCV Core Expressing Hepatocytes
por: Rizza, Stacey A., et al.
Publicado: (2011)

Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
por: Chapman, Rosamund, et al.
Publicado: (2013)

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation
por: Kumar, R, et al.
Publicado: (2012)

Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design
por: Hu, Duoyi, et al.
Publicado: (2017)

Structural definition of a conserved neutralization epitope on HIV-1 gp120
por: Zhou, Tongqing, et al.
Publicado: (2007)

Correction: Priming with Recombinant Auxotrophic BCG Expressing HIV-1 Gag, RT and Gp120 and Boosting with Recombinant MVA Induces a Robust T Cell Response in Mice
por: Chapman, Rosamund, et al.
Publicado: (2013)

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
por: Shen, Xiaoying, et al.
Publicado: (2020)

Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis
Publicado: (1992)

A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques
por: Lee, Sujin, et al.
Publicado: (2016)

Transforming epitope-specific gp120 monomer-based probes into immunogens with N-linked glycan masking
por: Chuang, G, et al.
Publicado: (2012)

The immunogenicity and protective immunity of multi-epitopes DNA prime-protein boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis
por: Zhang, Jianhui, et al.
Publicado: (2020)

Prime-Boost Vaccination Using Chemokine-Fused gp120 DNA and HIV Envelope Peptides Activates Both Immediate and Long-Term Memory Cellular Responses in Rhesus Macaques
por: Qin, Hong, et al.
Publicado: (2010)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

Focusing the immune response on the V3 loop of HIV-1 gp120 induces cross-clade neutralizing
por: Zolla-Pazner, Susan, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_hrehr00009j300vp29ctl2h8s9